FierceBiotech 2 ene 2026 Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease
FierceBiotech 2 ene 2026 AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
FierceBiotech 2 ene 2026 Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout
FierceBiotech 2 ene 2026 Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials
FierceBiotech 31 dic 2025 Quanterix's blood test for Alzheimer's disease uncovers potentially treatable population in decades-long study
FierceBiotech 30 dic 2025 Breast cancer tops list of most-studied diseases for 5th year in a row: report
FierceBiotech 23 dic 2025 Edwards nets FDA approval for Sapien M3 transcatheter mitral valve replacement
FierceBiotech 23 dic 2025 Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree
FierceBiotech 23 dic 2025 Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate
FierceBiotech 23 dic 2025 Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data
FierceBiotech 23 dic 2025 Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
FierceBiotech 22 dic 2025 BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement